<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603343</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT-Number 200400124330</org_study_id>
    <nct_id>NCT00603343</nct_id>
  </id_info>
  <brief_title>Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence</brief_title>
  <official_title>Treatment With Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence: Results of a Randomized Placebo-Controlled Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>APOGEPHA Arzneimittel GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>APOGEPHA Arzneimittel GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was conducted between 2004 and 2006 to prove efficacy and tolerability of the
      antimuscarinic propiverine compared to placebo in children suffering from non-neurogenic
      overactive bladder and urinary incontinence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial showed superior efficacy of propiverine over placebo and convincing
      tolerability for the treatment of children suffering from OAB and urinary incontinence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>voiding frequency</measure>
    <time_frame>before therapy and at end of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>voided volume</measure>
    <time_frame>before and at end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incontinence episodes per day</measure>
    <time_frame>before and at end of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety parameters: acute urinary retention, post void residual urine, urinalysis, ECG, blood pressure, pulse rate</measure>
    <time_frame>before and at end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Urinary Incontinence</condition>
  <condition>Children</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mictonetten 5 mg, coated tablet</intervention_name>
    <description>propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Mictonetten</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo corresponding to body weight</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  voiding frequency 8 or above per day

          -  at least one incontinence episode per day

          -  age between 5-10 years

          -  body weight between 17 and 45 kg

        Exclusion Criteria:

          -  normal age expected bladder capacity

          -  PVR more than 10 ml

          -  dysfunctional voiding

          -  neurogenic disorders

          -  UTI, constipation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Marschall-Kehrel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>urologist</affiliation>
  </overall_official>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <last_update_submitted>January 16, 2008</last_update_submitted>
  <last_update_submitted_qc>January 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>APOGEPHA</name_title>
    <organization>APOGEPHA Arzneimittel GmbH</organization>
  </responsible_party>
  <keyword>antimuscarinics</keyword>
  <keyword>children</keyword>
  <keyword>overactive bladder</keyword>
  <keyword>propiverine</keyword>
  <keyword>urinary incontinence</keyword>
  <keyword>urotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propiverine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

